CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Airbus Joins Air India A320 Altitude Drop Probe 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Add as a preferred source on Google
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
